CVRx, Inc.
Close on Oct 19, 2026
- Market cap
- $35.80M
- P/E (TTM)
- –
- Dividend yield
- –
About CVRx
Surgical & Medical Instruments & Apparatus, SIC 3841
CVRx is a commercial-stage medical device enterprise that designs, manufactures, and markets minimally invasive neuromodulation therapies for cardiovascular disease. The company's core product is Barostim, an implantable system featuring a pulse generator, a stimulation lead, and a wireless clinician programmer. It operates by delivering electrical pulses to carotid artery baroreceptors to counteract autonomic nervous system imbalances and ease symptoms of heart failure with reduced ejection fraction. Target customers primarily include hospitals, heart failure specialists, cardiologists, and surgeons.
The business commercializes its systems directly to healthcare facilities across the United States and Germany, while engaging independent distributors in Austria, Spain, and additional European territories. Its clinical research and trial footprint extends across multiple nations, including the United States, Germany, Italy, France, Canada, and the United Kingdom. Corporate headquarters are not stated in the provided text.
Summary of the business section of CVRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CVRx, Inc.
- Founded
- 2001
- Headquarters
- Minneapolis, MN
- Address
- 9201 West Broadway Avenue, Suite 650 55445
- Phone
- (763) 416-2850
- Website
- www.cvrx.com
- Employees
- 223, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Minneapolis, Minnesota
Stock & identifiers
- Ticker
- CVRX
- Exchange
- Nasdaq
- IPO date
- Jul 1, 2021
- Shares outstanding
- 27M, Jul 30, 2026
- Public float
- $112.40M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1235912
- CUSIP
- 126638105
- ISIN
- US1266381052
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kevin Hykes | PRES & CEO, Director | 284,237 |
| Brent Binkowski | CHIEF OPERATING OFFICER | 56,514 |
| Philip B. Adamson | Chief Medical Officer | 61,578 |
| Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | 34,000 |
| Jared Oasheim | CHIEF FINANCIAL OFFICER | 96,703 |
| Paul Verrastro | CHIEF MKTG & STRAT OFFICER | 60,551 |
| Robert Allen John | Chief Revenue Officer | 86,036 |
| Michael D. Dale | Director | 29,005 |
| Kirk G. Nielsen | Director | 1,918,854 |
| Kevin J. Ballinger | Director | 8,720 |
| Hill, Mitch C. | Director | 8,720 |
| Martha Shadan | Director | 8,720 |
| Mudit K. Jain | Director | 994,553 |
| Joseph P. Slattery | Director | 39,365 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 223 employees worldwide, all of which were employed on a full-time basis.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 25, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |